 Mark Connelly
Concepts (342)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Migraine Disorders | 11 | 2022 | 16 | 5.650 |
Why?
| | Pain | 14 | 2022 | 48 | 4.140 |
Why?
| | Arthritis, Juvenile | 10 | 2021 | 24 | 3.070 |
Why?
| | Pain Measurement | 12 | 2021 | 44 | 2.750 |
Why?
| | Adolescent | 40 | 2022 | 1976 | 2.490 |
Why?
| | Humans | 73 | 2022 | 6128 | 2.450 |
Why?
| | Telemedicine | 4 | 2022 | 68 | 2.330 |
Why?
| | Headache | 5 | 2017 | 15 | 2.210 |
Why?
| | Child | 43 | 2022 | 2874 | 2.140 |
Why?
| | Female | 46 | 2022 | 3367 | 2.060 |
Why?
| | Male | 45 | 2022 | 3284 | 1.960 |
Why?
| | Activities of Daily Living | 6 | 2019 | 13 | 1.940 |
Why?
| | Analgesics, Opioid | 4 | 2021 | 43 | 1.840 |
Why?
| | Surveys and Questionnaires | 12 | 2022 | 281 | 1.770 |
Why?
| | Pain Management | 9 | 2022 | 23 | 1.740 |
Why?
| | Adaptation, Psychological | 9 | 2021 | 38 | 1.470 |
Why?
| | Rheumatology | 3 | 2022 | 3 | 1.390 |
Why?
| | Quality of Life | 8 | 2021 | 116 | 1.290 |
Why?
| | Pain, Postoperative | 3 | 2014 | 44 | 1.250 |
Why?
| | Arthralgia | 3 | 2019 | 3 | 1.200 |
Why?
| | Fibromyalgia | 3 | 2021 | 4 | 1.200 |
Why?
| | Suicide | 2 | 2022 | 9 | 1.130 |
Why?
| | Parents | 3 | 2022 | 135 | 1.120 |
Why?
| | Medical Records | 4 | 2014 | 15 | 1.010 |
Why?
| | Self Report | 2 | 2020 | 41 | 0.970 |
Why?
| | Patient Acceptance of Health Care | 2 | 2020 | 46 | 0.970 |
Why?
| | Pediatrics | 5 | 2021 | 175 | 0.930 |
Why?
| | Firearms | 1 | 2022 | 10 | 0.920 |
Why?
| | Wounds, Gunshot | 1 | 2022 | 14 | 0.910 |
Why?
| | Membrane Proteins | 9 | 2001 | 56 | 0.900 |
Why?
| | Emergency Medical Services | 1 | 2021 | 14 | 0.900 |
Why?
| | Receptors, Immunologic | 9 | 2001 | 9 | 0.890 |
Why?
| | Receptors, Lipoprotein | 9 | 2001 | 14 | 0.880 |
Why?
| | Patient Education as Topic | 3 | 2019 | 65 | 0.880 |
Why?
| | Monitoring, Ambulatory | 1 | 2020 | 4 | 0.860 |
Why?
| | Smartphone | 1 | 2020 | 8 | 0.850 |
Why?
| | Emergency Service, Hospital | 5 | 2021 | 123 | 0.840 |
Why?
| | Emotions | 5 | 2017 | 19 | 0.810 |
Why?
| | Headache Disorders | 2 | 2019 | 3 | 0.800 |
Why?
| | Chronic Pain | 4 | 2019 | 27 | 0.800 |
Why?
| | Rheumatic Diseases | 1 | 2019 | 2 | 0.790 |
Why?
| | Dihydroergotamine | 1 | 2019 | 1 | 0.790 |
Why?
| | Massage | 1 | 2019 | 1 | 0.790 |
Why?
| | Aromatherapy | 1 | 2019 | 1 | 0.790 |
Why?
| | Psychotherapy | 1 | 2019 | 2 | 0.790 |
Why?
| | Self-Assessment | 2 | 2010 | 5 | 0.790 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2019 | 8 | 0.790 |
Why?
| | Inappropriate Prescribing | 1 | 2019 | 25 | 0.780 |
Why?
| | Decision Support Systems, Clinical | 1 | 2019 | 18 | 0.770 |
Why?
| | Primary Health Care | 1 | 2019 | 42 | 0.770 |
Why?
| | Clinical Protocols | 1 | 2019 | 35 | 0.760 |
Why?
| | Retrospective Studies | 10 | 2021 | 1196 | 0.760 |
Why?
| | Ambulatory Care | 1 | 2019 | 40 | 0.750 |
Why?
| | Stress, Psychological | 2 | 2011 | 35 | 0.740 |
Why?
| | Program Evaluation | 1 | 2019 | 49 | 0.740 |
Why?
| | Affect | 2 | 2010 | 10 | 0.730 |
Why?
| | Health Personnel | 3 | 2022 | 28 | 0.710 |
Why?
| | Pupil | 2 | 2015 | 3 | 0.700 |
Why?
| | Reflex, Pupillary | 2 | 2015 | 3 | 0.700 |
Why?
| | Prospective Studies | 10 | 2020 | 475 | 0.690 |
Why?
| | School Nursing | 1 | 2017 | 3 | 0.680 |
Why?
| | Delivery of Health Care | 3 | 2022 | 25 | 0.660 |
Why?
| | Students | 1 | 2017 | 35 | 0.650 |
Why?
| | Immunization | 1 | 2016 | 22 | 0.620 |
Why?
| | Young Adult | 6 | 2021 | 594 | 0.610 |
Why?
| | Neoplastic Cells, Circulating | 4 | 2017 | 4 | 0.580 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2014 | 2 | 0.550 |
Why?
| | Arthritis, Rheumatoid | 3 | 2014 | 9 | 0.550 |
Why?
| | Scoliosis | 1 | 2014 | 4 | 0.530 |
Why?
| | Amitriptyline | 1 | 2013 | 5 | 0.530 |
Why?
| | Antidepressive Agents, Tricyclic | 1 | 2013 | 6 | 0.530 |
Why?
| | Electronic Health Records | 2 | 2014 | 57 | 0.500 |
Why?
| | Adult | 11 | 2021 | 1107 | 0.460 |
Why?
| | Perception | 1 | 2012 | 11 | 0.460 |
Why?
| | Health Services | 1 | 2012 | 6 | 0.460 |
Why?
| | Quality of Health Care | 1 | 2011 | 18 | 0.440 |
Why?
| | Societies, Medical | 1 | 2011 | 44 | 0.440 |
Why?
| | Attitude to Health | 2 | 2016 | 35 | 0.430 |
Why?
| | Acupuncture Therapy | 2 | 2021 | 3 | 0.430 |
Why?
| | Musculoskeletal Pain | 3 | 2021 | 4 | 0.430 |
Why?
| | Anemia, Sickle Cell | 3 | 2006 | 17 | 0.420 |
Why?
| | Treatment Outcome | 10 | 2022 | 624 | 0.420 |
Why?
| | Lipoproteins, HDL | 6 | 2001 | 7 | 0.420 |
Why?
| | Health Behavior | 1 | 2011 | 71 | 0.410 |
Why?
| | Pilot Projects | 5 | 2021 | 123 | 0.410 |
Why?
| | Hospitals | 1 | 2010 | 37 | 0.400 |
Why?
| | Tension-Type Headache | 1 | 2009 | 1 | 0.400 |
Why?
| | Humidity | 1 | 2009 | 3 | 0.400 |
Why?
| | Weather | 1 | 2009 | 4 | 0.400 |
Why?
| | Pain Threshold | 1 | 2009 | 4 | 0.380 |
Why?
| | Severity of Illness Index | 6 | 2014 | 150 | 0.380 |
Why?
| | Predictive Value of Tests | 5 | 2014 | 103 | 0.370 |
Why?
| | Reproducibility of Results | 3 | 2020 | 186 | 0.370 |
Why?
| | Child, Preschool | 5 | 2020 | 1459 | 0.360 |
Why?
| | Cholesterol Esters | 5 | 2001 | 6 | 0.360 |
Why?
| | Cross-Sectional Studies | 4 | 2020 | 286 | 0.350 |
Why?
| | Disability Evaluation | 5 | 2022 | 10 | 0.340 |
Why?
| | Social Control, Informal | 1 | 2007 | 1 | 0.340 |
Why?
| | Expressed Emotion | 1 | 2007 | 1 | 0.340 |
Why?
| | Affective Symptoms | 1 | 2007 | 3 | 0.330 |
Why?
| | Health Status | 2 | 2014 | 22 | 0.330 |
Why?
| | Mass Screening | 2 | 2021 | 42 | 0.330 |
Why?
| | Pain, Intractable | 1 | 2006 | 1 | 0.320 |
Why?
| | Weight Reduction Programs | 2 | 2020 | 23 | 0.320 |
Why?
| | Musculoskeletal Diseases | 1 | 2006 | 2 | 0.320 |
Why?
| | Therapy, Computer-Assisted | 1 | 2006 | 2 | 0.320 |
Why?
| | Software | 1 | 2006 | 15 | 0.310 |
Why?
| | Feasibility Studies | 3 | 2021 | 61 | 0.300 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 3 | 2020 | 7 | 0.300 |
Why?
| | Middle Aged | 8 | 2019 | 557 | 0.280 |
Why?
| | Follow-Up Studies | 4 | 2020 | 308 | 0.280 |
Why?
| | Curriculum | 2 | 2021 | 17 | 0.280 |
Why?
| | Lupus Erythematosus, Systemic | 2 | 2015 | 9 | 0.270 |
Why?
| | Apolipoprotein A-I | 2 | 2000 | 2 | 0.260 |
Why?
| | Cholesterol | 5 | 2001 | 16 | 0.260 |
Why?
| | Cell Separation | 2 | 2013 | 5 | 0.260 |
Why?
| | Risk Assessment | 2 | 2022 | 132 | 0.250 |
Why?
| | Social Support | 2 | 2021 | 38 | 0.250 |
Why?
| | Hospitals, Pediatric | 2 | 2022 | 179 | 0.240 |
Why?
| | Registries | 2 | 2019 | 80 | 0.240 |
Why?
| | Avoidance Learning | 1 | 2022 | 6 | 0.240 |
Why?
| | Life Style | 2 | 2021 | 29 | 0.240 |
Why?
| | Age Factors | 3 | 2022 | 220 | 0.240 |
Why?
| | Receptors, Scavenger | 9 | 2001 | 9 | 0.230 |
Why?
| | Scavenger Receptors, Class B | 9 | 2001 | 9 | 0.230 |
Why?
| | Technology | 1 | 2022 | 2 | 0.230 |
Why?
| | Safety | 1 | 2022 | 15 | 0.230 |
Why?
| | Suicidal Ideation | 1 | 2022 | 7 | 0.230 |
Why?
| | United States | 2 | 2022 | 640 | 0.230 |
Why?
| | C-Reactive Protein | 2 | 2019 | 13 | 0.230 |
Why?
| | Biomarkers | 3 | 2019 | 118 | 0.220 |
Why?
| | Extracellular Space | 1 | 2001 | 4 | 0.220 |
Why?
| | Physicians | 1 | 2021 | 21 | 0.220 |
Why?
| | Pandemics | 1 | 2022 | 65 | 0.220 |
Why?
| | Recombinant Fusion Proteins | 1 | 2001 | 25 | 0.220 |
Why?
| | Mood Disorders | 2 | 2013 | 5 | 0.210 |
Why?
| | Adrenal Glands | 1 | 2000 | 7 | 0.210 |
Why?
| | Cholesterol, HDL | 1 | 2000 | 8 | 0.210 |
Why?
| | Practice Patterns, Physicians' | 1 | 2021 | 79 | 0.210 |
Why?
| | Transcutaneous Electric Nerve Stimulation | 1 | 2020 | 1 | 0.210 |
Why?
| | Nerve Block | 1 | 2020 | 1 | 0.210 |
Why?
| | Prochlorperazine | 1 | 2020 | 1 | 0.210 |
Why?
| | Ketorolac | 1 | 2020 | 1 | 0.210 |
Why?
| | Headache Disorders, Primary | 1 | 2020 | 1 | 0.210 |
Why?
| | Diphenhydramine | 1 | 2020 | 2 | 0.210 |
Why?
| | Mobile Applications | 1 | 2021 | 20 | 0.210 |
Why?
| | Patient Participation | 1 | 2020 | 20 | 0.210 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2020 | 22 | 0.210 |
Why?
| | Sleep Wake Disorders | 2 | 2019 | 15 | 0.200 |
Why?
| | Biomarkers, Tumor | 2 | 2017 | 37 | 0.200 |
Why?
| | Child, Hospitalized | 1 | 2020 | 27 | 0.200 |
Why?
| | Magnesium | 1 | 2019 | 4 | 0.200 |
Why?
| | Risk Factors | 2 | 2019 | 393 | 0.200 |
Why?
| | Internet | 1 | 2019 | 17 | 0.200 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2019 | 7 | 0.200 |
Why?
| | Evidence-Based Medicine | 1 | 2019 | 44 | 0.200 |
Why?
| | Infusions, Intravenous | 1 | 2019 | 24 | 0.200 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 52 | 0.190 |
Why?
| | Health Services Accessibility | 1 | 2019 | 32 | 0.190 |
Why?
| | Glycoproteins | 1 | 2019 | 10 | 0.190 |
Why?
| | Schools | 1 | 2019 | 38 | 0.190 |
Why?
| | Kidney Diseases | 1 | 2019 | 70 | 0.180 |
Why?
| | Cardiovascular Diseases | 1 | 2019 | 48 | 0.180 |
Why?
| | Fatigue | 2 | 2019 | 8 | 0.180 |
Why?
| | Antirheumatic Agents | 2 | 2019 | 10 | 0.180 |
Why?
| | Animals | 8 | 2001 | 896 | 0.180 |
Why?
| | Pediatric Obesity | 1 | 2020 | 117 | 0.180 |
Why?
| | Negotiating | 1 | 2017 | 2 | 0.170 |
Why?
| | Peer Group | 1 | 2017 | 9 | 0.170 |
Why?
| | Interpersonal Relations | 1 | 2017 | 13 | 0.170 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2017 | 2 | 0.170 |
Why?
| | Lung Neoplasms | 1 | 2017 | 20 | 0.170 |
Why?
| | Caregivers | 2 | 2010 | 38 | 0.170 |
Why?
| | School Health Services | 1 | 2017 | 10 | 0.170 |
Why?
| | Adolescent Behavior | 1 | 2017 | 48 | 0.160 |
Why?
| | Aged | 5 | 2019 | 304 | 0.160 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 97 | 0.160 |
Why?
| | Sleep | 2 | 2021 | 32 | 0.160 |
Why?
| | Health Expenditures | 1 | 2016 | 12 | 0.160 |
Why?
| | Infant | 3 | 2016 | 1399 | 0.160 |
Why?
| | COS Cells | 6 | 2001 | 21 | 0.150 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2016 | 2 | 0.150 |
Why?
| | Inflammation Mediators | 1 | 2015 | 8 | 0.150 |
Why?
| | Colorectal Neoplasms | 1 | 2016 | 15 | 0.150 |
Why?
| | Health Education | 2 | 2014 | 36 | 0.150 |
Why?
| | Recurrence | 2 | 2006 | 106 | 0.150 |
Why?
| | Eye | 1 | 2015 | 1 | 0.150 |
Why?
| | Iris | 1 | 2015 | 1 | 0.150 |
Why?
| | Time Factors | 1 | 2016 | 273 | 0.140 |
Why?
| | Upper Extremity Deep Vein Thrombosis | 1 | 2015 | 1 | 0.140 |
Why?
| | Catheterization, Central Venous | 1 | 2015 | 18 | 0.140 |
Why?
| | Prognosis | 2 | 2017 | 179 | 0.140 |
Why?
| | Writing | 1 | 2014 | 1 | 0.140 |
Why?
| | Problem Solving | 1 | 2014 | 2 | 0.140 |
Why?
| | Self Disclosure | 1 | 2014 | 6 | 0.140 |
Why?
| | CD-ROM | 1 | 2014 | 1 | 0.130 |
Why?
| | Early Medical Intervention | 1 | 2014 | 2 | 0.130 |
Why?
| | Medical Informatics | 1 | 2014 | 7 | 0.130 |
Why?
| | Biological Products | 1 | 2014 | 2 | 0.130 |
Why?
| | Pleural Effusion, Malignant | 1 | 2013 | 1 | 0.130 |
Why?
| | Brain | 2 | 2012 | 92 | 0.130 |
Why?
| | Self Care | 1 | 2014 | 23 | 0.130 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2013 | 4 | 0.130 |
Why?
| | Epithelial Cells | 1 | 2013 | 6 | 0.130 |
Why?
| | Social Adjustment | 1 | 2012 | 4 | 0.120 |
Why?
| | Infant, Newborn | 1 | 2016 | 887 | 0.120 |
Why?
| | Memory, Short-Term | 1 | 2012 | 1 | 0.120 |
Why?
| | Sensitivity and Specificity | 2 | 2013 | 144 | 0.120 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2012 | 3 | 0.120 |
Why?
| | Cell Membrane | 3 | 2001 | 7 | 0.120 |
Why?
| | Cognition | 1 | 2012 | 28 | 0.120 |
Why?
| | Osteoarthritis, Knee | 1 | 2012 | 1 | 0.120 |
Why?
| | Neoplasms | 1 | 2013 | 96 | 0.110 |
Why?
| | Parent-Child Relations | 1 | 2012 | 32 | 0.110 |
Why?
| | Precipitating Factors | 1 | 2011 | 1 | 0.110 |
Why?
| | Obesity | 1 | 2012 | 116 | 0.110 |
Why?
| | Cytoplasm | 2 | 2001 | 10 | 0.100 |
Why?
| | Mice | 3 | 2001 | 453 | 0.100 |
Why?
| | Aged, 80 and over | 3 | 2017 | 115 | 0.100 |
Why?
| | Psychology, Child | 1 | 2010 | 11 | 0.100 |
Why?
| | Social Behavior | 1 | 2010 | 12 | 0.100 |
Why?
| | Attitude of Health Personnel | 1 | 2010 | 53 | 0.100 |
Why?
| | Rats | 2 | 2001 | 208 | 0.100 |
Why?
| | Disclosure | 1 | 2007 | 8 | 0.090 |
Why?
| | Nurse's Role | 1 | 2007 | 8 | 0.090 |
Why?
| | Galvanic Skin Response | 1 | 2007 | 1 | 0.080 |
Why?
| | Heart Rate | 1 | 2007 | 24 | 0.080 |
Why?
| | Prevalence | 1 | 2007 | 137 | 0.080 |
Why?
| | Self Efficacy | 1 | 2007 | 30 | 0.080 |
Why?
| | Syndrome | 1 | 2006 | 30 | 0.080 |
Why?
| | Cohort Studies | 2 | 2019 | 256 | 0.080 |
Why?
| | Chronic Disease | 1 | 2006 | 111 | 0.080 |
Why?
| | Cognition Disorders | 1 | 2006 | 14 | 0.080 |
Why?
| | Incidence | 2 | 2015 | 131 | 0.070 |
Why?
| | Phobic Disorders | 1 | 2022 | 4 | 0.060 |
Why?
| | Qualitative Research | 1 | 2022 | 31 | 0.060 |
Why?
| | Fear | 1 | 2022 | 15 | 0.060 |
Why?
| | Administration, Oral | 1 | 2022 | 63 | 0.060 |
Why?
| | Communication | 1 | 2022 | 52 | 0.060 |
Why?
| | Base Sequence | 2 | 2000 | 114 | 0.060 |
Why?
| | Insurance, Health | 1 | 2022 | 16 | 0.060 |
Why?
| | Sex Factors | 1 | 2022 | 77 | 0.060 |
Why?
| | Homeostasis | 1 | 2001 | 16 | 0.060 |
Why?
| | Pain Perception | 1 | 2021 | 3 | 0.060 |
Why?
| | Missouri | 1 | 2022 | 83 | 0.060 |
Why?
| | Professional-Patient Relations | 1 | 2021 | 9 | 0.060 |
Why?
| | Terminology as Topic | 1 | 2021 | 14 | 0.060 |
Why?
| | Biological Transport, Active | 1 | 2001 | 4 | 0.060 |
Why?
| | Protein Structure, Tertiary | 1 | 2001 | 17 | 0.050 |
Why?
| | Peptide Fragments | 1 | 2001 | 17 | 0.050 |
Why?
| | Clinical Competence | 1 | 2021 | 37 | 0.050 |
Why?
| | Exercise Therapy | 1 | 2021 | 5 | 0.050 |
Why?
| | Patient Dropouts | 1 | 2021 | 3 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2021 | 15 | 0.050 |
Why?
| | Phospholipids | 1 | 2000 | 6 | 0.050 |
Why?
| | Decision Support Techniques | 1 | 2020 | 8 | 0.050 |
Why?
| | Hypnotics and Sedatives | 1 | 2020 | 5 | 0.050 |
Why?
| | Dopamine Antagonists | 1 | 2020 | 3 | 0.050 |
Why?
| | Quality Improvement | 1 | 2021 | 63 | 0.050 |
Why?
| | Organic Anion Transporters | 1 | 2000 | 5 | 0.050 |
Why?
| | Fatty Acids | 1 | 2000 | 4 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 68 | 0.050 |
Why?
| | Lipid Metabolism | 1 | 2000 | 9 | 0.050 |
Why?
| | Neoplasm Proteins | 1 | 2000 | 22 | 0.050 |
Why?
| | Tumor Suppressor Proteins | 1 | 2000 | 11 | 0.050 |
Why?
| | Diet | 1 | 2021 | 52 | 0.050 |
Why?
| | Carrier Proteins | 1 | 2000 | 35 | 0.050 |
Why?
| | Patient Compliance | 1 | 2021 | 73 | 0.050 |
Why?
| | Body Mass Index | 1 | 2020 | 138 | 0.050 |
Why?
| | Lipoproteins, LDL | 1 | 1999 | 3 | 0.050 |
Why?
| | Physical Therapy Modalities | 1 | 2019 | 4 | 0.050 |
Why?
| | Antidepressive Agents | 1 | 2019 | 6 | 0.050 |
Why?
| | DNA Primers | 1 | 1999 | 41 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 2 | 2012 | 87 | 0.050 |
Why?
| | Models, Psychological | 1 | 2017 | 8 | 0.040 |
Why?
| | Survival Analysis | 1 | 2017 | 47 | 0.040 |
Why?
| | Histones | 1 | 2017 | 33 | 0.040 |
Why?
| | Anxiety | 1 | 2017 | 40 | 0.040 |
Why?
| | Depression | 1 | 2017 | 61 | 0.040 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 61 | 0.040 |
Why?
| | Immunomagnetic Separation | 1 | 2016 | 1 | 0.040 |
Why?
| | Lipids | 1 | 2015 | 7 | 0.040 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2015 | 9 | 0.040 |
Why?
| | Up-Regulation | 1 | 2015 | 29 | 0.040 |
Why?
| | Case-Control Studies | 1 | 2015 | 130 | 0.040 |
Why?
| | Reference Values | 1 | 2015 | 44 | 0.040 |
Why?
| | North Carolina | 1 | 2015 | 2 | 0.040 |
Why?
| | Odds Ratio | 1 | 2015 | 47 | 0.040 |
Why?
| | Aging | 1 | 2015 | 39 | 0.040 |
Why?
| | Logistic Models | 1 | 2015 | 92 | 0.030 |
Why?
| | African Americans | 1 | 2015 | 109 | 0.030 |
Why?
| | Walking | 1 | 2014 | 34 | 0.030 |
Why?
| | Paracentesis | 1 | 2013 | 3 | 0.030 |
Why?
| | Disease Management | 1 | 2014 | 36 | 0.030 |
Why?
| | Models, Biological | 1 | 2014 | 48 | 0.030 |
Why?
| | Cadherins | 1 | 2013 | 8 | 0.030 |
Why?
| | Prostatic Neoplasms | 1 | 2013 | 9 | 0.030 |
Why?
| | Bone Neoplasms | 1 | 2013 | 20 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2013 | 66 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2012 | 17 | 0.030 |
Why?
| | Overweight | 1 | 2012 | 41 | 0.030 |
Why?
| | Lipoproteins, HDL3 | 2 | 2001 | 2 | 0.030 |
Why?
| | Transfection | 2 | 2001 | 32 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2000 | 120 | 0.030 |
Why?
| | Ultrasonography, Doppler, Transcranial | 1 | 2006 | 2 | 0.020 |
Why?
| | Memory | 1 | 2006 | 2 | 0.020 |
Why?
| | Intelligence Tests | 1 | 2006 | 4 | 0.020 |
Why?
| | Psychomotor Performance | 1 | 2006 | 6 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2006 | 17 | 0.020 |
Why?
| | Educational Status | 1 | 2006 | 14 | 0.020 |
Why?
| | Magnetic Resonance Angiography | 1 | 2006 | 6 | 0.020 |
Why?
| | Attention | 1 | 2006 | 12 | 0.020 |
Why?
| | Southeastern United States | 1 | 2005 | 2 | 0.020 |
Why?
| | Regression Analysis | 1 | 2005 | 60 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2005 | 72 | 0.020 |
Why?
| | Cholesterol Oxidase | 1 | 2001 | 1 | 0.010 |
Why?
| | Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent | 1 | 2001 | 1 | 0.010 |
Why?
| | Phospholipases A | 1 | 2000 | 1 | 0.010 |
Why?
| | Sphingomyelins | 1 | 2000 | 1 | 0.010 |
Why?
| | Lipoproteins, HDL2 | 1 | 2000 | 1 | 0.010 |
Why?
| | Phosphatidylcholines | 1 | 2000 | 2 | 0.010 |
Why?
| | Kinetics | 1 | 2000 | 36 | 0.010 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2000 | 1 | 0.010 |
Why?
| | Amino Acid Motifs | 1 | 2000 | 2 | 0.010 |
Why?
| | Cross-Linking Reagents | 1 | 2000 | 2 | 0.010 |
Why?
| | Scavenger Receptors, Class A | 1 | 2000 | 5 | 0.010 |
Why?
| | Biological Transport | 1 | 2000 | 15 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2000 | 68 | 0.010 |
Why?
| | Protein Binding | 1 | 2000 | 49 | 0.010 |
Why?
| | Binding Sites | 1 | 2000 | 50 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2000 | 11 | 0.010 |
Why?
| | Helix-Loop-Helix Motifs | 1 | 2000 | 2 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 2000 | 16 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2000 | 13 | 0.010 |
Why?
| | Leucine Zippers | 1 | 2000 | 15 | 0.010 |
Why?
| | I-kappa B Kinase | 1 | 2000 | 4 | 0.010 |
Why?
| | Isoenzymes | 1 | 2000 | 19 | 0.010 |
Why?
| | Cell Line | 1 | 2000 | 105 | 0.010 |
Why?
| | Adrenal Cortex | 1 | 1999 | 1 | 0.010 |
Why?
| | Proteoglycans | 1 | 1999 | 4 | 0.010 |
Why?
| | Arteriosclerosis | 1 | 1999 | 1 | 0.010 |
Why?
| | Apolipoproteins | 1 | 1999 | 3 | 0.010 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|